Results 151 to 160 of about 91,544 (273)

Extramedullary Disease—Achilles Heel in Myeloma?

open access: yesAmerican Journal of Hematology, Volume 101, Issue 3, Page 521-536, March 2026.
ABSTRACT Despite advances in therapy, extramedullary disease (EMD) remains an aggressive form of multiple myeloma associated with poor outcomes. Patients with true EMD, in which plasmacytomas have become completely independent of bone, have a particularly poor prognosis. The pathogenesis of EMD is driven by complex mechanisms involving loss of adhesion
Shaji Kumar   +7 more
wiley   +1 more source

CD38 [PDF]

open access: yesScience-Business eXchange, 2013
openaire   +1 more source

Loss of CD38 antigen on CD34+CD38+ cells during short-term culture [PDF]

open access: yesLeukemia, 2000
D, von Laer   +7 more
openaire   +2 more sources

Survival and Prognostic Factors of 215 Post‐Transplant Lymphoproliferative Disorders After Solid Organ Transplantations in a Finnish Nationwide Population‐Based Study Over 30 Years

open access: yesHematological Oncology, Volume 44, Issue 2, March 2026.
ABSTRACT Post‐transplant lymphoproliferative disorder (PTLD) is a rare, dreaded complication of organ transplantation with major clinical challenges. We conducted a nationwide population‐based study of all solid organ transplant (SOT) recipients (n = 6555), both adults and children, over a 30‐year period in Finland.
Terhi K. Friman   +11 more
wiley   +1 more source

Aging‐Derived Alterations in Genomic, Immune, and Metabolic Networks: Implications for Cancer Development and Therapy

open access: yesMedComm – Oncology, Volume 5, Issue 1, March 2026.
Ageing acts as a double‐edged sword in cancer. In the elderly, open chromatin, immunosenescence, and chronic inflammation drive SASP (IL‐6, MMPs), MDSC accumulation and T‐cell suppression, fostering tumor‐promoting microenvironments and limited therapeutic benefit.
Qi Wang   +7 more
wiley   +1 more source

Enhanced Detection of Multiple Myeloma Cells by Next‐Generation Flow Cytometry Following Density Gradient Medium Separation

open access: yesEuropean Journal of Haematology, Volume 116, Issue 3, Page 256-266, March 2026.
ABSTRACT Introduction Following treatment, relapse of Multiple Myeloma (MM) occurs due to measurable residual disease (MRD). As therapeutic options expand, advances in response assessment become more critical, necessitating more sensitive MRD detection methods.
Aisling O'Brien   +2 more
wiley   +1 more source

Cytokine Dynamics in Bortezomib‐Induced Peripheral Neuropathy: Challenges in Translating Preclinical Findings to Humans

open access: yesJournal of the Peripheral Nervous System, Volume 31, Issue 1, March 2026.
ABSTRACT Background and Aims Bortezomib‐induced peripheral neuropathy (BIPN) remains a common treatment side effect in patients with multiple myeloma (MM). Data from rodent models indicate a role of proinflammatory cytokines in BIPN pathophysiology, making them potential therapeutic targets.
Nadine Cebulla   +18 more
wiley   +1 more source

Changes of B cell subsets characterized with CD27 and CD38 phenotypes in peripheral blood of myasthenia gravis patients

open access: yesChinese Journal of Contemporary Neurology and Neurosurgery, 2019
Objective To investigate the clinical significance of peripheral B-cell subsets with CD27 and CD38 phenotypes in myasthenia gravis (MG) patients. Methods Peripheral blood samples of 43 MG patients and 38 health controls (HC) from January 2016 to Decamber
Jian⁃hua JIANG   +6 more
doaj  

Home - About - Disclaimer - Privacy